Stewart CF - Search Results

1

Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.

Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB 3rd, Stewart CF. Turner DC, et al. Among authors: stewart cf. Clin Cancer Res. 2014 May 15;20(10):2783-92. doi: 10.1158/1078-0432.CCR-13-2364. Epub 2014 Mar 17. Clin Cancer Res. 2014. PMID: 24637635 Free PMC article. Clinical Trial.

2

Disposition of high-dose methotrexate in an obese cancer patient.

Fleming RA, Eldridge RM, Johnson CE, Stewart CF. Fleming RA, et al. Among authors: stewart cf. Cancer. 1991 Sep 15;68(6):1247-50. doi: 10.1002/1097-0142(19910915)68:6<1247::aid-cncr2820680611>3.0.co;2-o. Cancer. 1991. PMID: 1714790

3

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.

Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Stewart CF, et al. J Clin Oncol. 1994 Sep;12(9):1946-54. doi: 10.1200/JCO.1994.12.9.1946. J Clin Oncol. 1994. PMID: 8083716 Clinical Trial.

4

Phase I study of topotecan for pediatric patients with malignant solid tumors.

Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, et al. Pratt CB, et al. J Clin Oncol. 1994 Mar;12(3):539-43. doi: 10.1200/JCO.1994.12.3.539. J Clin Oncol. 1994. PMID: 8120551 Clinical Trial.

5

Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.

Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H, Kearns C, Stute N, Crom WR, Evans WE. Rodman JH, et al. Among authors: stewart cf. Semin Oncol. 1993 Feb;20(1):18-29. Semin Oncol. 1993. PMID: 8475406 Review.

6

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Baker SD, et al. Among authors: stewart cf. Cancer Chemother Pharmacol. 1996;37(3):195-202. doi: 10.1007/BF00688317. Cancer Chemother Pharmacol. 1996. PMID: 8529278

7

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Furman WL, et al. Among authors: stewart cf. J Clin Oncol. 1996 May;14(5):1504-11. doi: 10.1200/JCO.1996.14.5.1504. J Clin Oncol. 1996. PMID: 8622064 Clinical Trial.

8

Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.

Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ. Tubergen DG, et al. Among authors: stewart cf. J Pediatr Hematol Oncol. 1996 Nov;18(4):352-61. doi: 10.1097/00043426-199611000-00004. J Pediatr Hematol Oncol. 1996. PMID: 8888741 Clinical Trial.

9

Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.

Stewart CF, Zamboni WC, Crom WR, Houghton PJ. Stewart CF, et al. Cancer Chemother Pharmacol. 1997;40(3):259-65. doi: 10.1007/s002800050656. Cancer Chemother Pharmacol. 1997. PMID: 9219511

10

Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.

Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF. Zamboni WC, et al. Among authors: stewart cf. Clin Cancer Res. 1998 Feb;4(2):455-62. Clin Cancer Res. 1998. PMID: 9516936

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

322 results

Search Page